Arena Pharmaceuticals, Inc. (ARNA) Misses Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Arena Pharma (ARNA) Posts Modest BELVIQ Sales, BMO Capital Notes
May 13, 2014 8:02 AM EDTBMO Capital analyst Jim Birchenough, M.D. reiterated a Market Perform rating on Arena Pharma (NASDAQ: ARNA) following a Q1 net loss of $0.12 versus the consensus of a $0.10 loss, and an ending cash balance of $256.5 million.
The analyst also highlights revenues were $6.8 million, including $2.9 million in net product sales of weight loss drug BELVIQ, of which $2.7 million... More
